Glycomimetics Inc Stock Ownership - Who owns Glycomimetics?

Insider buying vs selling

Have Glycomimetics Inc insiders been buying or selling?
Rachel K. KingDirector2024-03-293,334$3.00
Mark Alan GoldbergDirector2024-03-294,584$3.00
Daniel M. JuniusDirector2024-03-295,209$3.00
Patricia S. AndrewsDirector2023-12-295,191$2.36
Rachel K. KingDirector2023-12-294,238$2.36
Mark Alan GoldbergDirector2023-12-295,827$2.36
Patricia S. AndrewsDirector2023-09-308,167$1.50
Mark Alan GoldbergDirector2023-09-309,167$1.50
Rachel K. KingDirector2023-09-306,667$1.50
Edwin RockChief Medical Officer2023-09-2230,403$1.38

1 of 2

GLYC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GLYC insiders and whales buy or sell their stock.

GLYC Shareholders

What type of owners hold Glycomimetics Inc stock?
Scott D. Sandell21.81%14,056,571$3.33MInsider
M. James Barrett20.45%13,182,418$3.12MInsider
Peter J. Barris20.45%13,182,418$3.12MInsider
Bvf Inc14.81%9,544,262$2.26MInstitution
Artal Group Sa13.32%8,589,064$2.04MInstitution
Invus Public Equities LP13.32%8,589,064$2.04MInsider
New Enterprise Associates 10 L P7.75%4,995,664$1.18MInsider
New Enterprise Associates 13 LP6.35%4,093,377$970.13kInsider
Nea Management Company LLC5.95%3,835,039$908.90kInstitution
Octagon Capital Advisors LP4.65%3,000,000$711.00kInstitution

1 of 3

GLYC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GLYC36.65%63.35%Net BuyingNet Buying
LYRA74.73%14.19%Net Buying
SNSE9.21%71.96%Net Selling
MNPR2.01%97.99%Net BuyingNet Buying

Glycomimetics Stock Ownership FAQ

Who owns Glycomimetics?

Glycomimetics (NASDAQ: GLYC) is owned by 57.16% institutional shareholders, 98.81% Glycomimetics insiders, and 0.00% retail investors. Scott D. Sandell is the largest individual Glycomimetics shareholder, owning 14.06M shares representing 21.81% of the company. Scott D. Sandell's Glycomimetics shares are currently valued at $3.40M.

If you're new to stock investing, here's how to buy Glycomimetics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.